生物世界·2025-06-24 06:18Core Viewpoint - Semaglutide, developed by Novo Nordisk, is a GLP-1 receptor agonist that suppresses appetite and reduces caloric intake, approved for treating type 2 diabetes and weight loss. Its emergence has disrupted the weight loss drug market, with sales exceeding $7.8 billion in Q1 this year. However, Eli Lilly's Tizepatide has surpassed Semaglutide's weight loss records, achieving an average weight reduction of 20.2% in a head-to-head clinical trial [2][3]. Group 1: Sales and Market Impact - Tizepatide's sales in Q1 have already exceeded $6.1 billion, narrowing the gap with Semaglutide [3]. - The clinical trial results published in NEJM indicate that Tizepatide outperforms Semaglutide in weight loss effectiveness [2][3]. Group 2: Clinical Trials and Results - The REDEFINE 1 trial showed that the combination of Cagrilintide and Semaglutide resulted in an average weight loss of 20.4% over 68 weeks among non-diabetic overweight/obese participants, with 34.7% losing ≥25% of their body weight [11][13]. - In the REDEFINE 2 trial, the same combination led to a 13.7% average weight loss in overweight/obese participants with type 2 diabetes, significantly higher than the placebo group [17][19]. Group 3: Health Benefits and Safety - Cagrilintide and Semaglutide combination therapy showed improvements in various health metrics, including a 9.9 mmHg reduction in systolic blood pressure compared to 3.2 mmHg in the placebo group [13]. - The incidence of gastrointestinal adverse events was higher in the combination therapy group (79.6%) compared to the placebo group (39.9%), but most events were transient and mild to moderate in severity [14][20].